|
- 积分
- 50
- 威望
- 50
- 包包
- 232
|
Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers
0 z& [( S. ?! r$ tYuan Lina,1, Haipeng Zhanga,1, Jiankai Lianga,1, Kai Lia, Wenbo Zhua, Liwu Fub, Fang Wangb, Xiaoke Zhengc, Huijuan Shic, Sihan Wua, Xiao Xiaoa, Lijun Chena, Lipeng Tanga, Min Yana, Xiaoxiao Yanga, Yaqian Tana, Pengxin Qiua, Yijun Huanga, Wei Yind, Xinwen Sua, Haiyan Hue, Jun Huf,2, and Guangmei Yana,2
% v* z$ U8 ]7 x6 d8 oAuthor Affiliations6 ^- Q+ n, ~) m
' U0 P) ]5 a) n, O( NEdited* by Bernard Roizman, University of Chicago, Chicago, IL, and approved September 10, 2014 (received for review May 12, 2014)
& m# R5 F0 R2 [0 o% r. H+ H2 i
, L. B7 Z z% W/ E2 ~AbstractAuthors & InfoSIMetricsRelated ContentPDFPDF + SI0 O5 |6 u7 a) C% H
Significance# l3 U; X6 X& J5 W9 P, t
/ k( Q9 J' |. n! T, n2 h; Z
Although oncolytic virotherapy is showing great promise in clinical trials, not all patients are benefiting. Identifying predictors of therapeutic effectiveness for each oncolytic virus would provide a good chance to increase response rate. Here, we describe an alphavirus (M1) that possesses selective and potent antitumor activity through intravenous infusion, whereas its replication is controlled by the zinc-finger antiviral protein (ZAP) gene. A survey of cancer tissue banks reveals that ZAP is commonly deficient in human cancers, suggesting extensive application prospects of M1. Our work provides an example of a potentially personalized cancer therapy using a targeted oncolytic virus that can be selectively administered to patients with ZAP-deficient tumors. We predict that such agents will form the armamentarium of cancer therapy in the future.
. i) E V) K2 E- @
. t4 X7 o3 h' HAbstract
/ b ^1 I" }( a/ o; M0 KOncolytic virotherapy is a growing treatment modality that uses replicating viruses as selective antineoplastic agents. Safety and efficacy considerations dictate that an ideal oncolytic agent would discriminate between normal and cancer cells on the basis of common genetic abnormalities in human cancers. Here, we identify a naturally occurring alphavirus (M1) as a novel selective killer targeting zinc-finger antiviral protein (ZAP)-deficient cancer cells. In vitro, in vivo, and ex vivo studies showed potent oncolytic efficacy and high tumor tropism of M1. We showed that the selectivity depends on ZAP deficiency by systematic identification. A large-scale multicenter pathology study using tissue microarrays reveals that ZAP is commonly deficient in human cancers, suggesting extensive application prospects for M1. Additionally, M1 killed cancer cells by inducing endoplasmic reticulum stress-mediated apoptosis. Our report provides novel insights into potentially personalized cancer therapy using oncolytic viruses |
-
总评分: 威望 + 2
包包 + 10
查看全部评分
|
发表于 2014-10-14 12:49
发表于 2014-10-14 16:25
